The Preventive Intervention Center at the University of Iowa is conducting a study to find out if a new test can predict who may develop cognitive problems due to Alzheimer's disease based on their genes. This research will also test an investigational medication to see if it can delay the symptoms of cognitive disorders.
Adults aged 65-83 may qualify to participate in this study.
Eligible participants receive at no cost:
Memory and thinking evaluations
You may receive compensation for time and travel. The study will last about 5 years and include 5 clinic visits the first year, then 2 visits a year until the end of the study.
To learn more, email us at email@example.com or call 319/353-8233 or 1-800/887-6917.
Study Coordinator: Erin Balkenende 319-353-8233 (firstname.lastname@example.org)
Principal Investigator: 319-384-5030 (email@example.com)
Healthy volunteers ages 18 to 55, with no serious medical conditions or current pain, are invited to participate in a study involving temporary muscle soreness from an infusion of a slightly acidic or normal saline solution. Visits also include questionnaires, collecting a saliva sample, and sensations of pressure, heat or cold water on the arm. There will be three visits: approximately 1.5 hours/visit.
Contact Jackie Loesche at 319-335-9795 or email firstname.lastname@example.org
We are currently recruiting healthy participants who consume less than 500mg of caffeine per week for a research study that examines the effect of caffeine on motor memory. If you choose to participate, you will be assigned to one of two groups: one group will receive a caffeine pill after learning a new motor skill, and another group will receive a placebo pill after learning a new motor skill. All subjects will visit the laboratory for two consecutive days, for 30-60 minutes each day. During these sessions, you will complete a fine motor task repeatedly. If interested, please contact Sara at email@example.com
Sara at firstname.lastname@example.org
Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution
Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.
Please refer to www.clinicaltrials.gov for more information identifier NCT01266265
Pulmonary Hypertension Program
Cynthia Larew RN 319-356-1028 pager # 2123
The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.
Please refer to www.clinicaltrials.gov identifier NCT00614510 for more information.
Cardiomyopathy Treatment Program
Page Scovel, RN
Please help us improve your experience on our website by completing a brief survey
Yes, I'll give feedback No, Thanks
Your browser does not support iframes.